Hong Kong Life Sciences Stock News

Shanghai Fudan Microelectronics Group reported its earnings for the nine months ended September 30, 2025, showing revenue of CNY 3,024.45 million and net income of CNY 330.29 million, alongside a proposed amendment to its Articles of Association. While year-to-date revenue increased compared to the prior year, the company's net income and earnings per share both declined, highlighting pressures on profitability despite top-line gains. We’ll explore how the decline in net income despite...

China Communications Construction (SEHK:1800) reported its earnings for the first nine months of 2025, highlighting declines in both revenue and net income compared to the same period last year. This has drawn close attention from investors. See our latest analysis for China Communications Construction. Despite softer earnings this year, China Communications Construction’s share price has held steady in the short term and is now trading at HK$5.2. Momentum has faded lately, as shown by the...

Agricultural Bank of China recently completed a major RMB 40.00 billion issuance of Additional Tier 1 Capital Bonds and reported higher year-on-year net income for the third quarter of 2025. The combination of a strengthened capital base from the bond issuance and improved profitability provides important signals regarding the bank's operational health and future flexibility. We'll explore how the successful bond issuance could shape the bank's capital strength and influence its long-term...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

China International Capital Corporation Limited recently announced that its shareholders approved an interim cash dividend and elected Ms. Tian Ting as employee director at the October 31, 2025 extraordinary general meeting, while also amending its Articles of Association. The company also reported very large year-over-year increases in revenue and net income for the first nine months of 2025, reflecting improved operational performance. We'll examine how this substantial earnings growth...

In early November 2025, CStone Pharmaceuticals reported regulatory approval in China for Phase clinical trials of its innovative tri-specific antibody CS2009 for advanced solid tumors and revealed the first international presentation of its bispecific antibody CS2015 at the ACAAI Annual Scientific Meeting in the United States. These developments not only highlight progress in CStone’s R&D pipeline but also mark an important step in gaining broader global scientific recognition for its novel...

BOC Hong Kong (Holdings) Limited recently announced a third quarter dividend of HK$0.29 per share for the period ended September 30, 2025, with the ex-dividend date on November 12, 2025, record date on November 20, and payment date on November 26. This dividend affirmation delivers certainty and highlights the company's commitment to consistent shareholder returns, which can bolster investor confidence. With the third quarter dividend now confirmed, we'll explore how reliable dividend...

On October 28, 2025, Everest Medicines Limited announced it had entered into an exclusive licensing agreement with Visara Inc. to develop, manufacture, and commercialize VIS-101, a novel bifunctional biologic for wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion, in Greater China, Singapore, South Korea, and select Southeast Asian countries, with upfront, milestone, and royalty payments totaling up to US$89 million plus additional expenses. This...

It might be of some concern to shareholders to see the China Tobacco International (HK) Company Limited ( HKG:6055...

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) drew attention at the 2025 Chinese Congress on Holistic Integrative Oncology with presentations on sacituzumab tirumotecan, its TROP2 ADC therapy. The company detailed encouraging safety data and regulatory momentum across several cancer types. See our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical. Sichuan Kelun-Biotech Biopharmaceutical’s breakthrough cancer drug developments have grabbed headlines, but what’s really fueled...

Jiangxi Copper Company Limited announced on October 28, 2025, the approval of amendments to its Articles of Association at an EGM, alongside the appointment of Mr. Liu Zhihong as an Independent Non-executive Director and new committee member, and released nine-month earnings showing year-over-year growth in sales and net income. The combination of improved financial results and governance changes suggests an evolution in corporate strategy and oversight at Jiangxi Copper. We’ll explore how...

China Oilfield Services Limited recently reported its earnings results for the nine months ended September 30, 2025, highlighting revenue of CNY34.85 billion and net income of CNY3.21 billion, both up from the same period last year. A rise in basic earnings per share from continuing operations, CNY0.67 versus CNY0.51 a year ago, signals improved profitability and enhanced operational efficiency. We'll examine how China Oilfield Services' improved revenue and profit performance could...

Key Insights Using the 2 Stage Free Cash Flow to Equity, JD Health International fair value estimate is HK$46.16 JD...

In recent days, Tencent Holdings shares moved higher following positive macroeconomic developments in China, including easing trade tensions, the lifting of certain export curbs, and encouraging inflation data. An interesting aspect is that this optimism in the Chinese technology sector also impacted Prosus, a major shareholder with a significant stake in Tencent Holdings. We'll now explore how renewed investor confidence amid easing trade tensions may influence Tencent's investment outlook...

CSC Financial (SEHK:6066) just released its earnings results for the nine months ended September, showing a substantial jump in both revenue and net income. Investors are watching closely because these numbers often influence trading decisions. See our latest analysis for CSC Financial. CSC Financial’s latest surge in revenue and earnings seems to have caught the market’s attention, with the company’s share price rallying more than 44% since the start of the year. While momentum has cooled a...

With a price-to-earnings (or "P/E") ratio of 10.5x Pacific Textiles Holdings Limited ( HKG:1382 ) may be sending...

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

If you're looking at a mature business that's past the growth phase, what are some of the underlying trends that pop...

Insiders who bought HK$44.8m worth of Xinhua News Media Holdings Limited's ( HKG:309 ) stock at an average buy price of...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Key Insights The considerable ownership by individual investors in Poly Property Group indicates that they collectively...

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...

With a price-to-earnings (or "P/E") ratio of 15.3x RENHENG Enterprise Holdings Limited ( HKG:3628 ) may be sending...

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...